The disposition of Captopril, an angiotensin‐converting enzyme inhibitor with
antihypertensive properties, was studied in 10 normal male subjects after a single 100‐mg …

1. The converting-enzyme inhibitor captopril (25–50 mg orally every 6 h for 66 h) was used
to dissociate the circulating levels of angiotensin II (ANG II) from changes in sodium balance …

The kinetics of captopril plasma levels and of the drug‐induced plasma converting enzyme
activity (PCEA), plasma renin activity (PRA) and diastolic blood pressure (DBP) …

To compare the antihypertensive and Immoral effects of the angiotensin-converting enzyme
inhibitors captopril and enalapril, 20 patients with essential hypertension, not receiving …

The acute hypotensive effect of captopril 25 mg was investigated in 26 hypertensive patients
(11 with essential and 15 with renal arterial disease). Intra-arterial blood pressure was …

Captopril was administrated to 12 essential hypertensive patients with low or normal plasma
renin activity in order to evaluate its effectiveness in decreasing blood pressure and to …

The effects of the angiotensin converting enzyme inhibitor captopril were studied in 14
patients with essential or renovascular hypertension 75 minutes after ingestion of 25 mg of …

Angiotensin-converting enzyme (ACE) activity was found to be present within the rat aorta
using radioenzymatic techniques. Forty-two percent of the enzyme activity was localized …

A sensitive assay is described for quantitating plasma captopril levels. Captopril is an orally
active inhibitor of angiotensin-con-verting enzyme. Blood from patients taking this drug was …

1. Captopril was shown to be as effective as hydrochlorothiazide in lowering the blood
pressure in patients with moderately severe essential hypertension. 2. With the combination …